A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
NCT07444684
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Pyoderma Gangrenosum
Interventions
DRUG:
SHR-1139 Injection
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd